You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪医药-B(06996.HK)分别向现有股份受奖人及新股份受奖人授出446万个和1396万个受限制股份单位
格隆汇 09-22 23:09

格隆汇9月22日丨德琪医药-B(06996.HK)公吿,于2022年9月22日,董事会议决批准根据2022年受限制股份单位计划的条款向现有股份受奖人授出现有股份奖励,但须待彼等接纳后方可作实。此举涉及建议于授出日期向7名均为董事的现有股份受奖人授出合共446万个受限制股份单位。

于2022年9月22日,董事会议决批准按照2022年受限制股份单位计划的条款根据2022年一般授权向新股份受奖人授出新股份奖励,但须待彼等接纳后方可作实。此举涉及建议于授出日期向363名新股份受奖人(为集团雇员)授出合共1396万个受限制股份单位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account